locally-advanced-breast

Concurrent olaparib increased severe dermatitis during radiotherapy for inflammatory breast cancer

Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.